FindTrial
Sign In

Study on the value of soluble urokinase type plasminogen activator receptor (suPAR) in early prediction of acute renal injury in critically ill patients

Study on the value of soluble urokinase type plasminogen activator receptor (suPAR) in early prediction of acute renal injury in critically ill patients

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000031695
Enrollment
Unknown
Registered
2020-04-07
Start date
2020-04-01
Completion date
Unknown
Last updated
2020-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AKI

Interventions

Gold Standard:Clinical outcomes.
Index test:Soluble&#32
urokinase&#32
type&#32
plasminogen&#32
activator&#32
receptor&#32
(suPAR).

Sponsors

Laboratory of shaping District People's Hospital of Chongqing
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Aged >= 18 years; ICU patients with AKI diagnosis and complete clinical data.

Exclusion criteria

Exclusion criteria: Patients less than 24 hours in hospital, patients with nephropathy in hospital.

Design outcomes

Primary

MeasureTime frame
suPAR;SEN, SPE, ACC, AUC of ROC;—

Countries

China

Contacts

Public ContactChen Yao

Shapingba District People's Hospital of Chongqing

59563768@qq.com+86 18523580790

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026